Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nNOS siRNA is a small interfering RNA (siRNA) construct designed to silence the expression of the neuronal nitric oxide synthase (nNOS) gene, also known as NOS1. nNOS is a key enzyme in the central nervous system that catalyzes the production of nitric oxide (NO), a signaling molecule involved in neurotransmission, but also implicated in neurotoxicity and tumor progression when overproduced. By utilizing the RNA interference (RNAi) pathway, nNOS siRNA targets and facilitates the degradation of nNOS mRNA, thereby reducing protein levels and subsequent NO production. This experimental biologic is primarily used as a research tool in preclinical studies to investigate the role of nNOS in various pathologies, including neurodegenerative diseases like Parkinson's disease, central nervous system injuries such as traumatic brain injury and spinal cord injury, and certain cancers like melanoma and neuroblastoma. It is typically delivered using specialized systems such as liposomes, viral vectors (e.g., AAV), or nanoparticles to ensure cellular uptake and stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nNOS siRNA.